Phase I trial of combined therapy with bleomycin and the calmodulin antagonist, trifluoperazine View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1989-06

AUTHORS

William N. Hait, Steve Morris, John S. Lazo, Robert J. Figlin, Henry J. Durivage, Kathleen White, Peter E. Schwartz

ABSTRACT

Calmodulin antagonists, such as trifluoperazine, can enhance the cytotoxic effects of bleomycin both in tissue culture and in vivo. Therefore, we evaluated the effects of combination treatment with these drugs in a phase I clinical trial. Patients with objectively measurable or evaluable cancer refractory to conventional treatment who had an acceptable performance status (ECOG 0-2) and acceptable laboratory studies were eligible. All patients gave written informed consent. A cycle of therapy consisted of three weekly treatments with trifluoperazine (days 1-4) and 30 IU bleomycin (day 3). After three patients completed a cycle of therapy without experiencing dose-limiting toxicity, new patients were entered in the study and received a higher dose of trifluoperazine. The dose of bleomycin remained constant. Evaluable patients received at least 2 weeks of treatment and survived for 6 weeks; of 19 patients, 2 were unevaluable. The major toxicities were neurological and pulmonary and included one case of fatal pneumonia with interstitial pulmonary fibrosis. There was no hematologic toxicity. Two patients underwent partial responses (PRs) and two had complete responses (CRs). We conclude that trifluoperazine can safely be given with bleomycin and that further study of the potential efficacy of this treatment is indicated. More... »

PAGES

358-362

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf00435836

DOI

http://dx.doi.org/10.1007/bf00435836

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1014260881

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/2469543


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bleomycin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Evaluation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Trifluoperazine", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Yale University", 
          "id": "https://www.grid.ac/institutes/grid.47100.32", 
          "name": [
            "Department of Internal Medicine, Yale University School of Medicine, Comprehensive Cancer Center, 06510, New Haven, CT, USA", 
            "Department of Pharmacology, Yale University School of Medicine, Comprehensive Cancer Center, 06510, New Haven, CT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hait", 
        "givenName": "William N.", 
        "id": "sg:person.0770161004.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0770161004.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Yale University", 
          "id": "https://www.grid.ac/institutes/grid.47100.32", 
          "name": [
            "Department of Pharmacology, Yale University School of Medicine, Comprehensive Cancer Center, 06510, New Haven, CT, USA", 
            "Department of Obstetrics and Gynecology, Yale University School of Medicine, Comprehensive Cancer Center, 06510, New Haven, CT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Morris", 
        "givenName": "Steve", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Yale University", 
          "id": "https://www.grid.ac/institutes/grid.47100.32", 
          "name": [
            "Department of Pharmacology, Yale University School of Medicine, Comprehensive Cancer Center, 06510, New Haven, CT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lazo", 
        "givenName": "John S.", 
        "id": "sg:person.0667110640.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0667110640.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of California Los Angeles", 
          "id": "https://www.grid.ac/institutes/grid.19006.3e", 
          "name": [
            "Department of Internal Medicine, University of California at Los Angeles, 50024, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Figlin", 
        "givenName": "Robert J.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Yale University", 
          "id": "https://www.grid.ac/institutes/grid.47100.32", 
          "name": [
            "Department of Internal Medicine, Yale University School of Medicine, Comprehensive Cancer Center, 06510, New Haven, CT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Durivage", 
        "givenName": "Henry J.", 
        "id": "sg:person.01371205350.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01371205350.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Yale University", 
          "id": "https://www.grid.ac/institutes/grid.47100.32", 
          "name": [
            "Department of Internal Medicine, Yale University School of Medicine, Comprehensive Cancer Center, 06510, New Haven, CT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "White", 
        "givenName": "Kathleen", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Yale University", 
          "id": "https://www.grid.ac/institutes/grid.47100.32", 
          "name": [
            "Department of Obstetrics and Gynecology, Yale University School of Medicine, Comprehensive Cancer Center, 06510, New Haven, CT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schwartz", 
        "givenName": "Peter E.", 
        "id": "sg:person.01207015645.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01207015645.37"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf00258116", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002540542", 
          "https://doi.org/10.1007/bf00258116"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00258116", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002540542", 
          "https://doi.org/10.1007/bf00258116"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0190-9622(87)70004-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003976326"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/b978-0-12-525960-6.50027-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004399239"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/1097-0142(197304)31:4<903::aid-cncr2820310422>3.0.co;2-n", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010699930"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0006-291x(77)80108-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013579427"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0014-4827(82)90094-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020072281"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00254251", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021580527", 
          "https://doi.org/10.1007/bf00254251"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00254251", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021580527", 
          "https://doi.org/10.1007/bf00254251"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0014-5793(78)80772-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022708030"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1073/pnas.75.8.3771", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022980292"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0024-3205(85)90120-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028492015"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0024-3205(85)90120-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028492015"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0360-3016(86)90173-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031473291"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0006-2952(85)90374-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034019770"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0006-2952(85)90374-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034019770"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0006-291x(80)90849-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034384648"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0006-291x(77)80107-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038901917"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1073/pnas.75.11.5432", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041040708"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0006-291x(82)91272-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043286483"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/80.4.246", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059814968"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1126/science.6203171", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1062635716"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1126/science.6243188", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1062635816"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.7326/0003-4819-93-4-533", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1073738173"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.7326/0003-4819-98-3-304", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1073740230"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077613891", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1078811593", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1986.4.6.994", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1078813744"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079059347", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1988.6.5.880", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1079706990"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1081998172", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082219511", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1989-06", 
    "datePublishedReg": "1989-06-01", 
    "description": "Calmodulin antagonists, such as trifluoperazine, can enhance the cytotoxic effects of bleomycin both in tissue culture and in vivo. Therefore, we evaluated the effects of combination treatment with these drugs in a phase I clinical trial. Patients with objectively measurable or evaluable cancer refractory to conventional treatment who had an acceptable performance status (ECOG 0-2) and acceptable laboratory studies were eligible. All patients gave written informed consent. A cycle of therapy consisted of three weekly treatments with trifluoperazine (days 1-4) and 30 IU bleomycin (day 3). After three patients completed a cycle of therapy without experiencing dose-limiting toxicity, new patients were entered in the study and received a higher dose of trifluoperazine. The dose of bleomycin remained constant. Evaluable patients received at least 2 weeks of treatment and survived for 6 weeks; of 19 patients, 2 were unevaluable. The major toxicities were neurological and pulmonary and included one case of fatal pneumonia with interstitial pulmonary fibrosis. There was no hematologic toxicity. Two patients underwent partial responses (PRs) and two had complete responses (CRs). We conclude that trifluoperazine can safely be given with bleomycin and that further study of the potential efficacy of this treatment is indicated.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/bf00435836", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2435356", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1088364", 
        "issn": [
          "0344-5704", 
          "1432-0843"
        ], 
        "name": "Cancer Chemotherapy and Pharmacology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "23"
      }
    ], 
    "name": "Phase I trial of combined therapy with bleomycin and the calmodulin antagonist, trifluoperazine", 
    "pagination": "358-362", 
    "productId": [
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf00435836"
        ]
      }, 
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "43f01c8a90f5f41173cdc5275ac38f87bbf14d6e12c025c348954448ba4ec731"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1014260881"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7806519"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "2469543"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf00435836", 
      "https://app.dimensions.ai/details/publication/pub.1014260881"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-15T09:03", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000375_0000000375/records_91462_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/BF00435836"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf00435836'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf00435836'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf00435836'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf00435836'


 

This table displays all metadata directly associated to this object as RDF triples.

244 TRIPLES      21 PREDICATES      69 URIs      33 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf00435836 schema:about N0d47b711ed8247e38ef0db2408e9e43d
2 N26f90461c28941cfb4ed9fc28fe994af
3 N27522287e659417c99f283bce00c8f7b
4 N28fe809d6c11435ea52d031a9890baa4
5 N3719e5a5464f4472a8296b154ebc39df
6 N60c064602d284e0eaa406b355bb0d193
7 N665fa9894e174b7fb7f53264fa9bc465
8 N6f21c12d425e4dd8988703c12280e3db
9 Nb14c1469d7364cf1822e5d3945b78232
10 Nb49859f61ef54dc7a47786d4f4c11b20
11 Nda192b68ff2d4efcbd2184f5d3fda63f
12 Ne50b8ab9a6e14b85abfe60e764841b94
13 anzsrc-for:11
14 anzsrc-for:1103
15 schema:author N7029cdb85b0047eaa8ebebffbc8ea5aa
16 schema:citation sg:pub.10.1007/bf00254251
17 sg:pub.10.1007/bf00258116
18 https://app.dimensions.ai/details/publication/pub.1077613891
19 https://app.dimensions.ai/details/publication/pub.1078811593
20 https://app.dimensions.ai/details/publication/pub.1079059347
21 https://app.dimensions.ai/details/publication/pub.1081998172
22 https://app.dimensions.ai/details/publication/pub.1082219511
23 https://doi.org/10.1002/1097-0142(197304)31:4<903::aid-cncr2820310422>3.0.co;2-n
24 https://doi.org/10.1016/0006-291x(80)90849-9
25 https://doi.org/10.1016/0006-291x(82)91272-4
26 https://doi.org/10.1016/0006-2952(85)90374-0
27 https://doi.org/10.1016/0014-4827(82)90094-5
28 https://doi.org/10.1016/0014-5793(78)80772-8
29 https://doi.org/10.1016/0024-3205(85)90120-1
30 https://doi.org/10.1016/0360-3016(86)90173-2
31 https://doi.org/10.1016/b978-0-12-525960-6.50027-4
32 https://doi.org/10.1016/s0006-291x(77)80107-1
33 https://doi.org/10.1016/s0006-291x(77)80108-3
34 https://doi.org/10.1016/s0190-9622(87)70004-8
35 https://doi.org/10.1073/pnas.75.11.5432
36 https://doi.org/10.1073/pnas.75.8.3771
37 https://doi.org/10.1093/jnci/80.4.246
38 https://doi.org/10.1126/science.6203171
39 https://doi.org/10.1126/science.6243188
40 https://doi.org/10.1200/jco.1986.4.6.994
41 https://doi.org/10.1200/jco.1988.6.5.880
42 https://doi.org/10.7326/0003-4819-93-4-533
43 https://doi.org/10.7326/0003-4819-98-3-304
44 schema:datePublished 1989-06
45 schema:datePublishedReg 1989-06-01
46 schema:description Calmodulin antagonists, such as trifluoperazine, can enhance the cytotoxic effects of bleomycin both in tissue culture and in vivo. Therefore, we evaluated the effects of combination treatment with these drugs in a phase I clinical trial. Patients with objectively measurable or evaluable cancer refractory to conventional treatment who had an acceptable performance status (ECOG 0-2) and acceptable laboratory studies were eligible. All patients gave written informed consent. A cycle of therapy consisted of three weekly treatments with trifluoperazine (days 1-4) and 30 IU bleomycin (day 3). After three patients completed a cycle of therapy without experiencing dose-limiting toxicity, new patients were entered in the study and received a higher dose of trifluoperazine. The dose of bleomycin remained constant. Evaluable patients received at least 2 weeks of treatment and survived for 6 weeks; of 19 patients, 2 were unevaluable. The major toxicities were neurological and pulmonary and included one case of fatal pneumonia with interstitial pulmonary fibrosis. There was no hematologic toxicity. Two patients underwent partial responses (PRs) and two had complete responses (CRs). We conclude that trifluoperazine can safely be given with bleomycin and that further study of the potential efficacy of this treatment is indicated.
47 schema:genre research_article
48 schema:inLanguage en
49 schema:isAccessibleForFree false
50 schema:isPartOf Nb50b5f89fb2c470aa0712cd060a1c1aa
51 Nfdcd1c0e8907447cb6660c90a44da30b
52 sg:journal.1088364
53 schema:name Phase I trial of combined therapy with bleomycin and the calmodulin antagonist, trifluoperazine
54 schema:pagination 358-362
55 schema:productId N07a1b023e1ea4530922b2570085e532d
56 N4c0f09ca13894bc7812e5dbf8b82c5ab
57 Na712ed3c934344779b7ba7e6c564b569
58 Nf462279fa1a94565a65c6202a9f5438a
59 Nf998a61d19b5433a869d52888e3c7e5e
60 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014260881
61 https://doi.org/10.1007/bf00435836
62 schema:sdDatePublished 2019-04-15T09:03
63 schema:sdLicense https://scigraph.springernature.com/explorer/license/
64 schema:sdPublisher Nf1d880c0a5884b548fe7643e6cf95ab3
65 schema:url http://link.springer.com/10.1007/BF00435836
66 sgo:license sg:explorer/license/
67 sgo:sdDataset articles
68 rdf:type schema:ScholarlyArticle
69 N07a1b023e1ea4530922b2570085e532d schema:name doi
70 schema:value 10.1007/bf00435836
71 rdf:type schema:PropertyValue
72 N083790949be849ad94ced4b193997f6a rdf:first N1b25bb9a0b9c44cda59a897c530640ae
73 rdf:rest Nebdc46e0404b4391bbd92ba9ffdcf754
74 N0d47b711ed8247e38ef0db2408e9e43d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
75 schema:name Trifluoperazine
76 rdf:type schema:DefinedTerm
77 N19377877abbf4a5f9bc9495784c06f10 schema:affiliation https://www.grid.ac/institutes/grid.47100.32
78 schema:familyName White
79 schema:givenName Kathleen
80 rdf:type schema:Person
81 N1b25bb9a0b9c44cda59a897c530640ae schema:affiliation https://www.grid.ac/institutes/grid.47100.32
82 schema:familyName Morris
83 schema:givenName Steve
84 rdf:type schema:Person
85 N26f90461c28941cfb4ed9fc28fe994af schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
86 schema:name Humans
87 rdf:type schema:DefinedTerm
88 N27522287e659417c99f283bce00c8f7b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
89 schema:name Bleomycin
90 rdf:type schema:DefinedTerm
91 N28fe809d6c11435ea52d031a9890baa4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
92 schema:name Neoplasms
93 rdf:type schema:DefinedTerm
94 N32cf56ecd6994d4191e334b43d117653 rdf:first sg:person.01371205350.10
95 rdf:rest Nd18dba740d334bce82d38249c9666852
96 N3719e5a5464f4472a8296b154ebc39df schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Male
98 rdf:type schema:DefinedTerm
99 N4c0f09ca13894bc7812e5dbf8b82c5ab schema:name readcube_id
100 schema:value 43f01c8a90f5f41173cdc5275ac38f87bbf14d6e12c025c348954448ba4ec731
101 rdf:type schema:PropertyValue
102 N56e5ab138faf4d989b931ca5f312f026 schema:affiliation https://www.grid.ac/institutes/grid.19006.3e
103 schema:familyName Figlin
104 schema:givenName Robert J.
105 rdf:type schema:Person
106 N60c064602d284e0eaa406b355bb0d193 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Antineoplastic Combined Chemotherapy Protocols
108 rdf:type schema:DefinedTerm
109 N665fa9894e174b7fb7f53264fa9bc465 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Drug Evaluation
111 rdf:type schema:DefinedTerm
112 N6f21c12d425e4dd8988703c12280e3db schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Adult
114 rdf:type schema:DefinedTerm
115 N7029cdb85b0047eaa8ebebffbc8ea5aa rdf:first sg:person.0770161004.32
116 rdf:rest N083790949be849ad94ced4b193997f6a
117 Na712ed3c934344779b7ba7e6c564b569 schema:name pubmed_id
118 schema:value 2469543
119 rdf:type schema:PropertyValue
120 Nb14c1469d7364cf1822e5d3945b78232 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Drug Administration Schedule
122 rdf:type schema:DefinedTerm
123 Nb49859f61ef54dc7a47786d4f4c11b20 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Female
125 rdf:type schema:DefinedTerm
126 Nb50b5f89fb2c470aa0712cd060a1c1aa schema:volumeNumber 23
127 rdf:type schema:PublicationVolume
128 Nc53e31605b774867890dbfd4d0c02009 rdf:first N56e5ab138faf4d989b931ca5f312f026
129 rdf:rest N32cf56ecd6994d4191e334b43d117653
130 Nd18dba740d334bce82d38249c9666852 rdf:first N19377877abbf4a5f9bc9495784c06f10
131 rdf:rest Nff1e5be9da3241a792e1ce96ce85f6c2
132 Nda192b68ff2d4efcbd2184f5d3fda63f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Middle Aged
134 rdf:type schema:DefinedTerm
135 Ne50b8ab9a6e14b85abfe60e764841b94 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Aged
137 rdf:type schema:DefinedTerm
138 Nebdc46e0404b4391bbd92ba9ffdcf754 rdf:first sg:person.0667110640.46
139 rdf:rest Nc53e31605b774867890dbfd4d0c02009
140 Nf1d880c0a5884b548fe7643e6cf95ab3 schema:name Springer Nature - SN SciGraph project
141 rdf:type schema:Organization
142 Nf462279fa1a94565a65c6202a9f5438a schema:name dimensions_id
143 schema:value pub.1014260881
144 rdf:type schema:PropertyValue
145 Nf998a61d19b5433a869d52888e3c7e5e schema:name nlm_unique_id
146 schema:value 7806519
147 rdf:type schema:PropertyValue
148 Nfdcd1c0e8907447cb6660c90a44da30b schema:issueNumber 6
149 rdf:type schema:PublicationIssue
150 Nff1e5be9da3241a792e1ce96ce85f6c2 rdf:first sg:person.01207015645.37
151 rdf:rest rdf:nil
152 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
153 schema:name Medical and Health Sciences
154 rdf:type schema:DefinedTerm
155 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
156 schema:name Clinical Sciences
157 rdf:type schema:DefinedTerm
158 sg:grant.2435356 http://pending.schema.org/fundedItem sg:pub.10.1007/bf00435836
159 rdf:type schema:MonetaryGrant
160 sg:journal.1088364 schema:issn 0344-5704
161 1432-0843
162 schema:name Cancer Chemotherapy and Pharmacology
163 rdf:type schema:Periodical
164 sg:person.01207015645.37 schema:affiliation https://www.grid.ac/institutes/grid.47100.32
165 schema:familyName Schwartz
166 schema:givenName Peter E.
167 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01207015645.37
168 rdf:type schema:Person
169 sg:person.01371205350.10 schema:affiliation https://www.grid.ac/institutes/grid.47100.32
170 schema:familyName Durivage
171 schema:givenName Henry J.
172 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01371205350.10
173 rdf:type schema:Person
174 sg:person.0667110640.46 schema:affiliation https://www.grid.ac/institutes/grid.47100.32
175 schema:familyName Lazo
176 schema:givenName John S.
177 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0667110640.46
178 rdf:type schema:Person
179 sg:person.0770161004.32 schema:affiliation https://www.grid.ac/institutes/grid.47100.32
180 schema:familyName Hait
181 schema:givenName William N.
182 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0770161004.32
183 rdf:type schema:Person
184 sg:pub.10.1007/bf00254251 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021580527
185 https://doi.org/10.1007/bf00254251
186 rdf:type schema:CreativeWork
187 sg:pub.10.1007/bf00258116 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002540542
188 https://doi.org/10.1007/bf00258116
189 rdf:type schema:CreativeWork
190 https://app.dimensions.ai/details/publication/pub.1077613891 schema:CreativeWork
191 https://app.dimensions.ai/details/publication/pub.1078811593 schema:CreativeWork
192 https://app.dimensions.ai/details/publication/pub.1079059347 schema:CreativeWork
193 https://app.dimensions.ai/details/publication/pub.1081998172 schema:CreativeWork
194 https://app.dimensions.ai/details/publication/pub.1082219511 schema:CreativeWork
195 https://doi.org/10.1002/1097-0142(197304)31:4<903::aid-cncr2820310422>3.0.co;2-n schema:sameAs https://app.dimensions.ai/details/publication/pub.1010699930
196 rdf:type schema:CreativeWork
197 https://doi.org/10.1016/0006-291x(80)90849-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034384648
198 rdf:type schema:CreativeWork
199 https://doi.org/10.1016/0006-291x(82)91272-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043286483
200 rdf:type schema:CreativeWork
201 https://doi.org/10.1016/0006-2952(85)90374-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034019770
202 rdf:type schema:CreativeWork
203 https://doi.org/10.1016/0014-4827(82)90094-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020072281
204 rdf:type schema:CreativeWork
205 https://doi.org/10.1016/0014-5793(78)80772-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022708030
206 rdf:type schema:CreativeWork
207 https://doi.org/10.1016/0024-3205(85)90120-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028492015
208 rdf:type schema:CreativeWork
209 https://doi.org/10.1016/0360-3016(86)90173-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031473291
210 rdf:type schema:CreativeWork
211 https://doi.org/10.1016/b978-0-12-525960-6.50027-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004399239
212 rdf:type schema:CreativeWork
213 https://doi.org/10.1016/s0006-291x(77)80107-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038901917
214 rdf:type schema:CreativeWork
215 https://doi.org/10.1016/s0006-291x(77)80108-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013579427
216 rdf:type schema:CreativeWork
217 https://doi.org/10.1016/s0190-9622(87)70004-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003976326
218 rdf:type schema:CreativeWork
219 https://doi.org/10.1073/pnas.75.11.5432 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041040708
220 rdf:type schema:CreativeWork
221 https://doi.org/10.1073/pnas.75.8.3771 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022980292
222 rdf:type schema:CreativeWork
223 https://doi.org/10.1093/jnci/80.4.246 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059814968
224 rdf:type schema:CreativeWork
225 https://doi.org/10.1126/science.6203171 schema:sameAs https://app.dimensions.ai/details/publication/pub.1062635716
226 rdf:type schema:CreativeWork
227 https://doi.org/10.1126/science.6243188 schema:sameAs https://app.dimensions.ai/details/publication/pub.1062635816
228 rdf:type schema:CreativeWork
229 https://doi.org/10.1200/jco.1986.4.6.994 schema:sameAs https://app.dimensions.ai/details/publication/pub.1078813744
230 rdf:type schema:CreativeWork
231 https://doi.org/10.1200/jco.1988.6.5.880 schema:sameAs https://app.dimensions.ai/details/publication/pub.1079706990
232 rdf:type schema:CreativeWork
233 https://doi.org/10.7326/0003-4819-93-4-533 schema:sameAs https://app.dimensions.ai/details/publication/pub.1073738173
234 rdf:type schema:CreativeWork
235 https://doi.org/10.7326/0003-4819-98-3-304 schema:sameAs https://app.dimensions.ai/details/publication/pub.1073740230
236 rdf:type schema:CreativeWork
237 https://www.grid.ac/institutes/grid.19006.3e schema:alternateName University of California Los Angeles
238 schema:name Department of Internal Medicine, University of California at Los Angeles, 50024, Los Angeles, CA, USA
239 rdf:type schema:Organization
240 https://www.grid.ac/institutes/grid.47100.32 schema:alternateName Yale University
241 schema:name Department of Internal Medicine, Yale University School of Medicine, Comprehensive Cancer Center, 06510, New Haven, CT, USA
242 Department of Obstetrics and Gynecology, Yale University School of Medicine, Comprehensive Cancer Center, 06510, New Haven, CT, USA
243 Department of Pharmacology, Yale University School of Medicine, Comprehensive Cancer Center, 06510, New Haven, CT, USA
244 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...